<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2406210832
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Aimovig
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ERENUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        70
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1343.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Amgen Manufacturing Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Amgen Manufacturing Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Novartis Europharm Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N02CX07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Aimovig contains the active substance erenumab. It belongs to a group of medicines called monoclonal antibodies.</p><p><br />Aimovig works by blocking the activity of the CGRP molecule, which has been linked to migraine (CGRP stands for calcitonin gene-related peptide).</p><p><br />Aimovig is used to prevent migraine in adults who have at least 4 migraine days per month when starting treatment with Aimovig.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not use Aimovig</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to erenumab or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p><strong>b. Warnings and precautions.</strong></p><p>Talk to your doctor before using Aimovig:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had an allergic reaction to rubber latex. The container of this medicinal product contains latex rubber within the cap.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from a cardiovascular disease. Aimovig has not been studied in patients with certain cardiovascular diseases.</p><p>&nbsp;</p><p>Talk to your doctor or get emergency medical help immediately:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get any symptoms of a serious allergic reaction, such as rash or swelling usually of the face, mouth, tongue, or throat; or difficulty breathing. Serious allergic reactions can happen within minutes, but some may happen more than one week after using Aimovig.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact a doctor if you get constipation and seek medical help immediately if you develop constipation with severe or constant belly (abdominal) pain and vomiting, swelling of abdomen or bloating. Constipation can occur when treated with Aimovig. It is usually mild or moderate in intensity. However, some patients using Aimovig have had constipation with serious complications and have been hospitalised. Some cases have required surgery.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children or adolescents (under 18&nbsp;years old) because the use of Aimovig has not been studied in this age group.</p><p>&nbsp;</p><p><strong>c. using other medicines and Aimovig</strong></p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p>&nbsp;</p><p><strong>d. pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Your doctor will decide whether you should stop using Aimovig during pregnancy.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>Monoclonal antibodies<u> </u>like Aimovig are known to pass into breast milk during the first few days after birth, but after this first period Aimovig can be used. Talk to your doctor about using Aimovig while breast‑feeding in order to help you decide whether you should stop breast‑feeding or stop using Aimovig.</p><p>&nbsp;</p><p><strong>e. Driving and using machines</strong></p><p>Aimovig is unlikely to affect your ability to drive and use machines.</p><p><strong>f. Important information about some of the ingredients of Aimovig.</strong></p><p><strong>Aimovig contains sodium</strong></p><p>Aimovig contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &ldquo;sodium‑free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p>If you have not noticed any treatment effect after 3&nbsp;months, tell your doctor who will decide whether you should continue treatment.</p><p>&nbsp;</p><p>Use Aimovig exactly as prescribed by your doctor. If your doctor prescribes the 70&nbsp;mg dose you should have one injection once every 4&nbsp;weeks. If your doctor prescribes the 140&nbsp;mg dose you should have either one injection of Aimovig 140&nbsp;mg or two injections of Aimovig 70&nbsp;mg once every 4&nbsp;weeks. If you are having two injections of Aimovig 70&nbsp;mg, the second injection must be given immediately after the first one at a different injection site. Make sure that you inject the entire contents of both pens.</p><p>&nbsp;</p><p>Aimovig is given as an injection under your skin (known as a subcutaneous injection). You or your caregiver can give the injection into your abdomen or your thigh. The outer area of your upper arm can also be used as an injection site, but only if someone else is giving you the injection. If you need 2&nbsp;injections, they should be given in different sites to avoid hardening of the skin and should not be given into areas where the skin is tender, bruised, red or hard.</p><p>&nbsp;</p><p>Your doctor or nurse will give you or your caregiver training in the right way to prepare and inject Aimovig. Do not try to inject Aimovig until this training has been given.</p><p>&nbsp;</p><p>Aimovig pens are for single use only.</p><p>&nbsp;</p><p>For detailed instructions on how to inject Aimovig, see &ldquo;Instructions for use of Aimovig pre‑filled pen&rdquo; at the end of this leaflet.</p><p>&nbsp;</p><p><strong>a.&nbsp;&nbsp;&nbsp; </strong><strong>If you use more Aimovig than you should</strong></p><p>If you have received more Aimovig than you should or if the dose has been given earlier than it should have been, tell your doctor.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp; </strong><strong>If you forget to use Aimovig</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget an Aimovig dose, take it as soon as possible after you realise.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Then contact your doctor, who will tell you when you should schedule your next dose. Follow the new schedule exactly as your doctor has told you.</p><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp; </strong><strong>If you stop using Aimovig</strong></p><p>Do not stop using Aimovig without talking to your doctor first. Your symptoms may return if you stop the treatment.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Possible side effects are listed below. Most of these side effects are mild to moderate.</p><p>&nbsp;</p><p><strong>Common: may affect up to 1 in </strong><strong>10&nbsp;people</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions such as rash, swelling, hives or difficulty breathing (see section&nbsp;2)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reactions, such as pain, redness and swelling where the injection is given.</p><p>&nbsp;</p><p>Aimovig may cause skin reactions such as rash, itching, hair loss or mouth/lip sores.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Keep the pen(s) in the outer carton in order to protect from light. Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.</p><p>&nbsp;</p><p>After Aimovig has been taken out of the refrigerator, it must be kept at room temperature (up to 30&deg;C) in the outer carton and must be used within 7 days, or else discarded. Do not put Aimovig back in the<br />refrigerator once it has been removed.</p><p>&nbsp;</p><p>Do not use this medicine if you notice that the solution contains particles, is cloudy or is distinctly yellow.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. There may be local regulations for disposal. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp;&nbsp; </strong><strong>What Aimovig contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is erenumab.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aimovig 70&nbsp;mg solution for injection in pre‑filled pen contains 70&nbsp;mg erenumab.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aimovig 140&nbsp;mg solution for injection in pre‑filled pen contains 140&nbsp;mg erenumab.</p><p>The other ingredients are sucrose, polysorbate 80, sodium hydroxide, glacial acetic acid, water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Aimovig solution for injection is clear to opalescent, colourless to light yellow, and practically free from particles.
	
	Aimovig is available in packs containing one single use pre filled pen and in multipacks containing 3 (3x1) pre filled pens.
	
	Not all pack sizes may be marketed.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Europharm limited, Ireland.</p><p>www.novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 12/2021 by EMA
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي أيموڤج على المادة الفعّالة إيرينوماب.&nbsp; ينتمي العقار إلى مجموعة من الأدوية تُسمى أجسامًا مضادة أحادية النسيلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعمل أيموڤج عن طريق حصر نشاط جزيء الببتيد المرتبط بجين الكالسيتونين، الذي لُوحظ ارتباطه بالصداع النصفي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستَخدَم أيموڤج للوقاية من الإصابة بالصداع نصفي في البالغين ممن يُصابون بصداع نصفي لمدة 4 أيام على الأقل في الشهر عند بدء العلاج بأيموڤج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال </strong><strong>أيموڤج</strong><strong> </strong><strong>:</strong></p><p dir="RTL">إذا كنت تعاني من حساسية تجاه إيرينوماب أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ب.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات عند استعمال </strong><strong>أيموڤج</strong></p><p dir="RTL">تحدَّث إلى طبيبك قبل استخدام أيموڤج في الحالات التَّالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصِبت من قبل بتفاعلات حساسية تجاه مادة اللاتكس المطاطية. تحتوي حاوية هذا المنتج الدَّوائي على مادة اللاتكس المطاطية داخل الغطاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض بالقلب والأوعية الدَّموية. لم تتم دراسة أيموڤج في المرضى ممن يُعانون من بعض أمراض القلب والأوعية الدَّموية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدَّث إلى طبيبك أو احصل على مساعدة طبية طارئة فورًا في الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت من أية أعراض تنم عن الإصابة بتفاعل حساسية خطير مثل الطفح الجلدي أو تورم عادة ما يكون بالوجه، أو الفم، أو اللسان أو الحَلْق أو صعوبة التنفس. قد تحدث تفاعلات حساسية خطيرة في غضون دقائق إلا أنه قد يحدث بعضها بعد انقضاء أكثر من أسبوع واحد على استخدام دواء أيموڤيج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بطبيب إذا عانيت من إمساك واطلب مساعدة طبية فورًا إذا عانيت من إمساك مصحوب بألم شديد أو مستمر في البطن وقيء أو تورُّم البطن أو انتفاخها. قد يحدث إمساك عند الخضوع للعلاج بدواء أيموڤيج. شدته عادة تكون بسيطة أو معتدلة. مع ذلك، فقد عانى بعض المرضى الذين استخدموا دواء أيموڤيج من إمساك مصحوب بمضاعفات خطيرة وتم إدخالهم المستشفى. تطلبت بعض الحالات جراحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا تعط هذا الدَّواء للأطفال أو المراهقين (دون 18 عامًا)؛ إذ لم تتم دراسة استخدام أيموڤج في هذه الفئة العمرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أدوية أخرى أو أعشاب أو مكملات غذائية.</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;د.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ قبل استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">سيقرر طبيبكِ ما إذا كان عليكِ إيقاف استخدام أيموڤج أثناء الحمل أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">تُعرف الأجسام المضادة أحادية النسيلة مثل أيموڤج بأنها تمر إلى لبن الأم خلال الأيام القليلة الأولى بعد الولادة، ولكن يمكن استخدام أيموڤج بعد انقضاء الفترة الأولى هذه. تحدَّثي إلى طبيبك حول استخدام أيموڤج أثناء ممارسة الرضاعة الطبيعيَّة؛ كي يُساعدك على اتخاذ قرار فيما يخص التَّوقف عن ممارسة الرضاعة الطبيعيَّة أو التَّوقف عن استخدام أيموڤج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. تأثير القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المرجح أن يُؤثر أيموڤج على قدرتك على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و.معلومات هامَّة حول عن بعض مكونات </strong><strong>أيموڤج</strong></p><p dir="RTL"><strong>يحتوي </strong><strong>أيموڤج</strong><strong> على الصوديوم</strong></p><p dir="RTL">يحتوي أيموڤج على أقل من 1 مليمول صوديوم (23 مجم) لكل جرعة، مما يعني أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. يُرجى مراجعة طبيبك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تلاحظ أي تأثير للعلاج بعد انقضاء 3 أشهر، أخبر طبيبك والذي سيقرر ما إذا كان ينبغي عليك مواصلة العلاج أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استخدم دواء أيموڤيج على النحو الذي وصفه طبيبك بالضبط. إذا وصف لك الطبيب الجرعة التي تبلغ 70 مجم، ينبغي عليك تلقي حقنة واحدة مرة واحدة كل 4 أسابيع. إذا وصف لك الطبيب الجرعة التي تبلغ 140 مجم، ينبغي عليك إما تلقي حقنة واحدة من إيموفيج 140 مجم أو تلقي حقنتين من عقار إيموفيج 70 مجم مرة واحدة كل 4 أسابيع. ينبغي إعطاء الحقن الثَّاني فور إعطاء الحَقن الأول في موضع حقن آخر. احرص على حقن جميع محتويات كلا القلمين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعطى أيموڤج في هيئة حقن أسفل الجلد. يمكنك أو بإمكان مقدم الرعاية الخاص بك إعطاء الحَقن بالبطن أو بالفخذ لديك. كما يمكن استخدام المنطقة الخارجية للجزء العلوي من الذراع كموضع حقن وذلك في حال أعطى شخص آخر الحقن لك.إذا كنت بحاجة إلى تلقي حقنتين، ينبغي إعطاؤهما في مواضع مختلفة؛ لتجنب تصلب الجلد وينبغي عدم إعطائهما في المناطق حيث الجلد الذي به ألم، مُصاب، أحمر أو صلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم طبيبك أو الممرض الخاص بك بتدريبك أو تدريب مقدم الرعاية الخاص بك على كيفية إعداد أيموڤج وحقنه بشكل صحيح. لا تحاول حقن أيموڤج إلى أن تنتهي من التَّدريب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعد أيموڤج أقلام للاستخدام مرة واحدة فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُمكِنك العثورعلى تعليمات مفصلة حول كيفية حقن أيموڤج في قسم: &quot;تعليمات استخدام أيموڤج قلم معبأ مسبقًا&quot; في نهاية هذه النَّشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الجرعة الزائدة من </strong><strong>أيموڤج</strong></p><p dir="RTL">أخبر طبيبك إذا تلقيت كمية أكبر مما ينبغي من أيموڤج أو إذا تم إعطاؤك الجرعة قبل الموعد المحدد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ب.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نسيان استعمال جرعة من </strong><strong>أيموڤج</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت إحدى جرعات أيموڤج، قم بتلقيها بمجرد تذكرك لها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم اتصل بطبيبك، وهو بدوره سيخبرك بمواعيد تلقي جرعتك التَّالية. اتبع جدول المواعيد الجديدة لاستخدم العقار دائمًا كما أخبرك طبيبك بالضبط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التوقف عن استعمال </strong><strong>أيموڤج</strong></p><p dir="RTL">لا تتوقف عن استعمال أيموڤج دون التَّحدث مع طبيبك أولًا. إذا قمت بإيقاف العلاج، فقد تعود الأعراض للظهور لديك مجددًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء أعراض جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يدرج أدناه الأعراض الجانبية المحتملة. تُعد غالبية هذه الأعراض الجانبية بسيطة إلى معتدلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تُؤثر على شخص واحد من كل 10&nbsp;أشخاص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية مثل الطفح الجلدي أو التورُّم أو الشرى (الأرتكاريا) أو صعوبة التَّنَفُّس (انظر قسم 2)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات عضلية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات بموضع الحقن مثل: ألم واحمرار وتورم بموضع الحَقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتسبب أيموڤج في الإصابة بتفاعلات بالجلد مثل: الطفح الجلدي أو الحكة أو تساقُط الشعر أو قرح في الفم/الشفتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أُصبت بأية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي أو الممرض.ويشمل ذلك أية أعراض جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.يمكنك أيضًا الإبلاغ عن الأعراض الجانبية بشكل مباشر.من خلال إبلاغك عن الأعراض الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصَّلاحية المدون على الملصق والعبوة الكرتونية بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بقلم (أقلام) الحقن داخل العبوة الكرتونية الخارجية لحمايتها من الضَّوء. يحفظ في الثلاجة (عند 2&mdash;8 درجة مئوية). لا تعرضه للتَّجميد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد إخراج أيموڤج من الثلاجة، يجب حفظه في درجة حرارة الغرفة (ما يصل إلى ٣٠ درجة مئوية) في العبوة الكرتونية الخارجية ويجب استخدامه في غضون ٧ يومًا، أو التَّخلصمنه. لا تقُم بإعادة أيموڤج إلى الثَّلاجة بعد إخراجه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدَّواء إذا لاحظت أنَّ المحلول يحتوي على أي جسيمات أو كان غائمًا أو ذا لون أصفر واضح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. قد تكون هناك لوائح محلية فيما يخص التَّخلص منها. ستُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما هي محتويات </strong><strong>أيموڤج</strong><strong>؟</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي إيرينوماب يحتوي كل قلم معبأ مسبقًا على 70 مجم من إيرينوماب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي سكروز، بوليسوربات 80، هيدروكسيد الصوديوم، حَمْض الخليك الثلجي، ماء للحقن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي عقار أيموڤيج 140 مجم محلول للحقن في قلم مُعبأ مسبقًا على 140 مجم إيرينوماب.</p><p dir="RTL">المكونات الأخرى هي سكروز، بوليسوربات 80، هيدروكسيد الصوديوم، حَمْض الخليك الثلجي، ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما </strong><strong>هو الشكل الصيدلاني لعقار أيموڤج ووصفه وحجم عبوته</strong></p><p dir="RTL">يُعد أيموڤج محلولًا مُعدًّا للحقن صافيًا إلى غائم، عديم اللون ويميل لونه إلى الأصفر الفاتح وهو عمليا خال من الجسيمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوافر أيموڤج في عبوات تحتوي على قلم واحد معبأ مسبقًا مُعد للاستخدام مرة واحدة وفي عبوات متعددة المحتوى بها 3 (3x1) أقلام معبأة مسبقًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التَّسويق لهذا المنتج هي ﺷﺮﻛﺔ ﻧﻮﻓﺎرﺗﺲ ﯾﻮروﻓﺎرم اﻟﻤﺤﺪودة، إﯾﺮﻟﻨﺪا</p><p dir="RTL">&nbsp; www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌د.	آخر تاريخ اعتماد لهذه النَّشرة من قبل وكالة الأدوية الأوروبية كان في 12/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aimovig 70 mg solution for injection in pre filled pen


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aimovig 70 mg solution for injection in pre filled pen
Each pre-filled pen contains 70 mg erenumab.

Erenumab is a fully human IgG2 monoclonal antibody produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection)

The solution is clear to opalescent, colourless to light yellow.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aimovig is indicated for prophylaxis of migraine in adults who have at least 4&nbsp;migraine days per month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated by physicians experienced in the diagnosis and treatment of migraine.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>Treatment is intended for patients with at least 4&nbsp;migraine days per month when initiating treatment with erenumab.</p><p>&nbsp;</p><p>The recommended dose is 70&nbsp;mg erenumab every 4&nbsp;weeks. Some patients may benefit from a dose of 140&nbsp;mg every 4&nbsp;weeks (see section&nbsp;5.1).</p><p>&nbsp;</p><p>Each 140&nbsp;mg dose is given either as one subcutaneous injection of 140&nbsp;mg or as two subcutaneous injections of 70&nbsp;mg.</p><p>&nbsp;</p><p>Clinical studies have demonstrated that the majority of patients responding to therapy showed clinical benefit within 3&nbsp;months. Consideration should be given to discontinuing treatment in patients who have shown no response after 3&nbsp;months of treatment. Evaluation of the need to continue treatment is recommended regularly thereafter.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Elderly (aged 65&nbsp;years and over)</em></p><p>Aimovig has not been studied in elderly patients. No dose adjustment is required as the pharmacokinetics of erenumab are not affected by age.</p><p>&nbsp;</p><p><em>Renal impairment / hepatic impairment</em></p><p>No dose adjustment is necessary in patients with mild to moderate renal impairment or hepatic impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Aimovig in children below the age of 18&nbsp;years have not yet been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Aimovig is for subcutaneous use.</p><p>&nbsp;</p><p>Aimovig is intended for patient self‑administration after proper training. The injections can also be given by another individual who has been appropriately instructed. The injection can be administered into the abdomen, thigh or into the outer area of the upper arm (the arm should be used only if the injection is being given by a person other than the patient; see section&nbsp;5.2). Injection sites should be rotated and injections should not be given into areas where the skin is tender, bruised, red or hard.</p><p>&nbsp;</p><p><em><u>Pre‑filled syringe</u></em></p><p>The entire contents of the Aimovig pre‑filled syringe should be injected. Each pre‑filled syringe is for single use only and designed to deliver the entire contents with no residual content remaining.</p><p>&nbsp;</p><p>Comprehensive instructions for administration are given in the instructions for use in the package leaflet.</p><p>&nbsp;</p><p><em><u>Pre‑filled pen</u></em></p><p>The entire contents of the Aimovig pre‑filled pen should be injected. Each pre‑filled pen is for single use only and designed to deliver the entire contents with no residual content remaining.</p><p>&nbsp;</p><p>Comprehensive instructions for administration are given in the instructions for use in the package leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients with certain major cardiovascular diseases were excluded from clinical studies (see section&nbsp;5.1). No safety data are available in these patients.</p><p>&nbsp;</p><p><u>Hypersensitivity reactions</u></p><p>&nbsp;</p><p>Serious hypersensitivity reactions, including rash, angioedema, and anaphylactic reactions, have been reported with erenumab in post-marketing experience. These reactions may occur within minutes, although some may occur more than one week after treatment. In that context, patients should be warned about the symptoms associated with hypersensitivity reactions. If a serious or severe hypersensitivity reaction occurs, initiate appropriate therapy and do not continue treatment with erenumab (see section&nbsp;4.3).</p><p>&nbsp;</p><p><u>Constipation</u></p><p>&nbsp;</p><p>Constipation is a common undesirable effect of Aimovig and is usually mild or moderate in intensity. In a majority of the cases, the onset was reported after the first dose of Aimovig; however patients have also experienced constipation later on in the treatment. In most cases constipation resolved within three months. In the post‑marketing setting, constipation with serious complications has been reported with erenumab. In some of these cases hospitalisation was required, including cases where surgery was necessary. History of constipation or the concurrent use of medicinal products associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation‑related complications. Patients should be warned about the risk of constipation and advised to seek medical attention in case constipation does not resolve or worsens. Patients should seek medical attention immediately if they develop severe constipation. Constipation should be managed promptly as clinically appropriate. For severe constipation, discontinuation of treatment should be considered.</p><p>&nbsp;</p><p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Latex‑sensitive individuals</u></p><p>&nbsp;</p><p>The removable cap of the Aimovig pre‑filled syringe/pen contains dry natural rubber latex, which may cause allergic reactions in individuals sensitive to latex.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No effect on exposure of co‑administered medicinal products is expected based on the metabolic pathways of monoclonal antibodies. No interaction with oral contraceptives (ethinyl estradiol/norgestimate) or sumatriptan was observed in studies with healthy volunteers.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are a limited amount of data from the use of erenumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section&nbsp;5.3). As a precautionary measure, it is preferable to avoid the use of Aimovig during pregnancy.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>It is unknown whether erenumab is excreted in human milk. Human IgGs are known to be excreted in breast milk during the first few days after birth, which is decreasing to low concentrations soon afterwards; consequently, a risk to the breast‑fed infant cannot be excluded during this short period. Afterwards, use of Aimovig could be considered during breast‑feeding only if clinically needed.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Animal studies showed no impact on female and male fertility (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aimovig is expected to have no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>A total of over 2,500&nbsp;patients (more than 2,600&nbsp;patient years) have been treated with Aimovig in registration studies. Of these, more than 1,300&nbsp;patients were exposed for at least 12&nbsp;months and 218&nbsp;patients were exposed for 5&nbsp;years. The overall safety profile of Aimovig remained consistent for 5&nbsp;years of long-term open-label treatment.</p><p>&nbsp;</p><p>The reported adverse drug reactions for 70&nbsp;mg and 140&nbsp;mg were injection site reactions (5.6%/4.5%), constipation (1.3%/3.2%), muscle spasms (0.1%/2.0%) and pruritus (0.7%/1.8%). Most of the reactions were mild or moderate in severity. Less than 2% of patients in these studies discontinued due to adverse events.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Table&nbsp;1 lists all adverse drug reactions that occurred in Aimovig‑treated patients during the 12‑week placebo‑controlled periods of the studies, as well as in the post‑marketing setting. Within each system organ class, the ADRs are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare&nbsp;(&lt;1/10,000).</p><p>&nbsp;</p><p><strong>Table&nbsp;1 List of adverse reactions</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:623px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>System Organ Class</p></td><td rowspan="2" style="vertical-align:top"><p>Adverse reaction</p></td><td rowspan="2" style="vertical-align:top"><p>Frequency category</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions<sup>a</sup> including anaphylaxis, angioedema, rash, swelling/oedema and urticaria</p></td><td style="vertical-align:top"><p>Common</p></td><td>&nbsp;</td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Common</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Oral sores<sup>b</sup></p></td><td style="vertical-align:top"><p>Not known</p></td><td>&nbsp;</td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Pruritus<sup>c</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Alopecia</p><p>Rash<sup>d</sup></p></td><td style="vertical-align:top"><p>Not known</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>Common</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Injection site reactions<sup>a</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td>&nbsp;</td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See section &ldquo;Description of selected adverse reactions&rdquo;</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral sores includes preferred terms of stomatitis, mouth ulceration, oral mucosal blistering.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pruritus includes preferred terms of generalised pruritus, pruritus and pruritic rash.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash includes preferred terms of rash papular, exfoliative rash, rash erythematous, urticaria, blister.</p></td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Injection site reactions</u></em></p><p>In the integrated 12‑week placebo‑controlled phase of the studies, injection site reactions were mild and mostly transient. There was one case of discontinuation in a patient receiving the 70&nbsp;mg dose due to injection site rash. The most frequent injection site reactions were localised pain, erythema and pruritus. Injection site pain typically subsided within 1&nbsp;hour after administration.</p><p>&nbsp;</p><p><em><u>Cutaneous and hypersensitivity reactions</u></em></p><p>In the integrated 12‑week placebo‑controlled phase of the studies, non‑serious cases of rash, pruritus and swelling/oedema were observed, which in the majority of cases were mild and did not lead to treatment discontinuation.</p><p>&nbsp;</p><p>In the post-marketing setting, cases of anaphylaxis and angiodoema were observed.</p><p>&nbsp;</p><p><em><u>Immunogenicity</u></em></p><p>During the double-blind treatment phase of the clinical studies, the incidence of anti‑erenumab antibody development was 6.3% (56/884) among subjects receiving a 70&nbsp;mg dose of erenumab (3 of whom had <em>in vitro</em> neutralising activity) and 2.6% (13/504) among subjects receiving the 140&nbsp;mg dose of erenumab (none of whom had <em>in vitro</em> neutralising activity). In an open-label study with up to 256&nbsp;weeks of treatment, the incidence of anti-erenumab antibody development was 11.0% (25/225) among patients who only received 70&nbsp;mg or 140&nbsp;mg of Aimovig throughout the entire study (2 of whom had <em>in vitro</em> neutralising activity). There was no impact of anti‑erenumab antibody development on the efficacy or safety of Aimovig.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia: </em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No cases of overdose have been reported in clinical studies.</p><p>&nbsp;</p><p>Doses up to 280&nbsp;mg have been administered subcutaneously in clinical studies with no evidence of dose‑limiting toxicity.</p><p>&nbsp;</p><p>In the event of an overdose, the patient should be treated symptomatically and supportive measures instituted as required.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</strong></p><p>&nbsp;</p><p>Pharmacotherapeutic group: Analgesics, antimigraine preparations, ATC code: N02CD01</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Erenumab is a human monoclonal antibody that binds to the calcitonin gene‑related peptide (CGRP) receptor. The CGRP receptor is located at sites that are relevant to migraine pathophysiology, such as the trigeminal ganglion. Erenumab potently and specifically competes with the binding of CGRP and inhibits its function at the CGRP receptor, and has no significant activity against other calcitonin family of receptors.</p><p>&nbsp;</p><p>CGRP is a neuropeptide that modulates nociceptive signalling and a vasodilator that has been associated with migraine pathophysiology. In contrast with other neuropeptides, CGRP levels have been shown to increase significantly during migraine and return to normal with headache relief. Intravenous infusion of CGRP induces migraine‑like headache in patients.</p><p>&nbsp;</p><p>Inhibition of the effects of CGRP could theoretically attenuate compensatory vasodilation in ischaemic‑related conditions. A study evaluated the effect of a single intravenous dose of 140&nbsp;mg Aimovig in subjects with stable angina under controlled exercise conditions. Aimovig showed similar exercise duration compared to placebo and did not aggravate myocardial ischaemia in these patients.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>Aimovig (erenumab) was evaluated for prophylaxis of migraine in two pivotal studies across the migraine spectrum in chronic and episodic migraine. In both studies, the patients enrolled had at least a 12‑month history of migraine (with or without aura) according to the International Classification of Headache Disorders (ICHD-III) diagnostic criteria. Elderly patients (&gt;65&nbsp;years), patients with opioid overuse in study in chronic migraine, patients with medication overuse in study in episodic migraine, and also patients with pre‑existing myocardial infarction, stroke, transient ischaemic attacks, unstable angina, coronary artery bypass surgery or other re‑vascularisation procedures within 12&nbsp;months prior to screening were excluded. Patients with poorly controlled hypertension or BMI &gt;40 were excluded from Study&nbsp;1.</p><p>&nbsp;</p><p><em><u>Chronic migraine</u></em></p><p><em>Study&nbsp;1</em></p><p>Erenumab was evaluated as monotherapy for prophylaxis of chronic migraine in a randomised, multicentre, 12‑week, placebo‑controlled, double‑blind study in patients suffering from migraine with or without aura (&ge;15&nbsp;headache days per month with &ge;8&nbsp;migraine days per month).</p><p>&nbsp;</p><p>667&nbsp;patients were randomised in a 3:2:2&nbsp;ratio to receive placebo (n&nbsp;=&nbsp;286) or 70&nbsp;mg (n&nbsp;=&nbsp;191) or 140&nbsp;mg (n&nbsp;=&nbsp;190) erenumab, stratified by the presence of acute medication overuse (present in 41% of overall patients). Patients were allowed to use acute headache treatments during the study.</p><p>&nbsp;</p><p>Demographics and baseline disease characteristics were balanced and comparable between study arms. Patients had a median age of 43&nbsp;years, 83% were female and 94% were white. The mean migraine frequency at baseline was approximately 18&nbsp;migraine days per month. Overall, 68% had failed one or more previous prophylactic pharmacotherapies due to lack of efficacy or poor tolerability, and 49% had failed two or more previous prophylactic pharmacotherapies due to lack of efficacy or poor tolerability. A total of 366 (96%) patients in the erenumab arms and 265 (93%) patients in the placebo arm completed the study (i.e. completed Week&nbsp;12 assessment).</p><p>&nbsp;</p><p>Reduction in mean monthly migraine days from placebo was observed in a monthly analysis from Month&nbsp;1 and in a follow‑up weekly analysis an onset of erenumab effect was seen from the first week of administration.</p><p>&nbsp;</p><p><strong>Figure&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change from baseline in monthly migraine days over time in Study&nbsp;1 (including primary endpoint at Month&nbsp;3)</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_87" o:spid="_x0000_i1026" type="#_x0000_t75"
 style='width:453.75pt;height:333pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ahmedar2/AppData/Local/Temp/4/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="605" height="444" src="file:///C:/Users/ahmedar2/AppData/Local/Temp/4/msohtmlclip1/01/clip_image002.jpg" /></p><p><strong>Table&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change from baseline in efficacy and patient‑reported outcomes at Week&nbsp;12 in Study&nbsp;1</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:641px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Aimovig (erenumab)<br />140&nbsp;mg</strong></p><p><strong>(n&nbsp;=&nbsp;187)</strong></p></td><td style="vertical-align:top"><p><strong>Aimovig (erenumab)<br />70&nbsp;mg</strong></p><p><strong>(n&nbsp;=&nbsp;188)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(n&nbsp;=&nbsp;281)</strong></p></td><td style="vertical-align:top"><p><strong>Treatment<br />difference<br />(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>p‑value</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong><u>Efficacy outcomes</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>MMD</strong></p><p>Mean change<br />(95% CI)</p><p>Baseline (SD)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑6.6<br />(‑7.5, ‑5.8)<br />17.8 (4.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑6.6<br />(‑7.5; ‑5.8)<br />17.9 (4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑4.2<br />(‑4.9, ‑3.5)<br />18.2 (4.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Both ‑2.5<br />(‑3.5, ‑1.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Both</p><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge;50% MMD responders</strong></p><p>Percentage [%]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>41.2%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>39.9%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>23.5%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n/a</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Both<br />&lt;0.001<sup>a,d</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge;75% MMD responders</strong></p><p>Percentage [%]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>20.9%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>17.0%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.8%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n/a</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n/a<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Monthly acute migraine‑<br />specific medication days</strong></p><p>Mean change (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>‑4.1<br />(‑4.7, ‑3.6)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>‑3.5<br />(‑4.0, ‑2.9)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>‑1.6<br />(‑2.1, ‑1.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>70&nbsp;mg:<br />‑1.9 (‑2.6, ‑1.1)</p><p>140&nbsp;mg:<br />&nbsp;‑2.6 (‑3.3, ‑1.8)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><br />Both</p><p>&lt;0.001<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (SD)</p></td><td style="vertical-align:top"><p>9.7 (7.0)</p></td><td style="vertical-align:top"><p>8.8 (7.2)</p></td><td style="vertical-align:top"><p>9.5 (7.6)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong><u>Patient‑reported outcome measures</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HIT‑6</strong></p><p>Mean change<sup>c</sup> (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑5.6<br />(‑6.5, ‑4.6)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑5.6<br />(‑6.5, ‑4.6)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑3.1<br />(‑3.9, ‑2.3)</p></td><td style="vertical-align:top"><p>70&nbsp;mg:<br />‑2.5 (‑3.7, ‑1.2)</p><p>140&nbsp;mg:<br />&nbsp;‑2.5 (‑3.7, ‑1.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n/a<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>MIDAS total<sup> </sup></strong></p><p>Mean change<sup>c</sup> (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑19.8<br />(‑25.6, ‑14.0)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑19.4<br />(‑25.2, ‑13.6)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑7.5<br />(‑12.4, ‑2.7)</p></td><td style="vertical-align:top"><p>70&nbsp;mg:<br />‑11.9 (‑19.3, ‑4.4)</p><p>140&nbsp;mg:<br />‑12.2 (‑19.7, ‑4.8)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n/a<sup>b</sup></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>CI&nbsp;=&nbsp;confidence interval; MMD = monthly migraine days; HIT‑6 = Headache Impact Test; MIDAS = Migraine Disability Assessment; n/a = not applicable.</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For secondary endpoints, all p‑values are reported as unadjusted p‑values and are statistically significant after adjustment for multiple comparisons.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For exploratory endpoints, no p‑value is presented.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For HIT-6: Change and reduction from baseline were evaluated in the last 4&nbsp;weeks of the 12‑week double‑blind treatment phase. For MIDAS: Change and reduction from baseline were evaluated over 12&nbsp;weeks. For data collection a recall period of 3&nbsp;months has been used.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p value was calculated based on the odds ratios.</p></td></tr></tbody></table><p>&nbsp;</p><p>In patients failing one or more prophylactic pharmacotherapies the treatment difference for the reduction of monthly migraine days (MMD) observed between erenumab 140&nbsp;mg and placebo was ‑3.3&nbsp;days (95% CI: ‑4.6, ‑2.1) and between erenumab 70&nbsp;mg and placebo ‑2.5&nbsp;days (95% CI: ‑3.8, ‑1.2). In patients failing two or more prophylactic pharmacotherapies the treatment difference was ‑4.3&nbsp;days (95% CI: ‑5.8; ‑2.8) between 140&nbsp;mg and placebo and ‑2.7&nbsp;days (95% CI: ‑4.2, ‑1.2) between 70&nbsp;mg and placebo. There was also a higher proportion of subjects treated with erenumab who achieved at least 50% reduction of MMD compared to placebo in the patients failing one or more prophylactic pharmacotherapies (40.8% for 140&nbsp;mg, 34.7% for 70&nbsp;mg versus 17.3% for placebo), with an odds ratio of 3.3 (95% CI: 2.0, 5.5) for 140&nbsp;mg and 2.6 (95% CI: 1.6, 4.5) for 70&nbsp;mg. In patients failing two or more prophylactic pharmacotherapies the proportion was 41.3% for 140&nbsp;mg and 35.6% for 70&nbsp;mg versus 14.2% for placebo with an odds ratio of 4.2 (95% CI: 2.2, 7.9) and 3.5 (95% CI: 1.8, 6.6), respectively.</p><p>&nbsp;</p><p>Approximately 41% of patients in the study had medication overuse. The treatment difference observed between erenumab 140&nbsp;mg and placebo and between erenumab 70&nbsp;mg and placebo for the reduction of MMD in these patients was ‑3.1&nbsp;days (95% CI: ‑4.8, ‑1.4) in both cases, and for the reduction of acute migraine‑specific medication days was ‑2.8 (95% CI: ‑4.2, ‑1.4) for 140&nbsp;mg and ‑3.3 (95% CI: ‑4.7, ‑1.9) for 70&nbsp;mg. There was a higher proportion of patients in the erenumab group who achieved at least a 50% reduction of MMD compared to placebo (34.6% for 140&nbsp;mg, 36.4% for 70&nbsp;mg versus 17.7% for placebo), with an odds ratio of 2.5 (95% CI: 1.3, 4.9) and 2.7 (95% CI: 1.4, 5.2), respectively.</p><p>&nbsp;</p><p>Efficacy was sustained for up to 1&nbsp;year in the open‑label extension of Study&nbsp;1 in which patients received 70&nbsp;mg and/or 140&nbsp;mg erenumab. 74.1% of patients completed the 52‑week extension. Pooled across the two doses, a reduction of ‑9.3&nbsp;MMD was observed after 52&nbsp;weeks relative to core study baseline. 59% of patients completing the study achieved a 50% response in the last month of the study.</p><p>&nbsp;</p><p><em><u>Episodic migraine</u></em></p><p><em>Study&nbsp;2</em></p><p>Erenumab was evaluated for prophylaxis of episodic migraine in a randomised, multicentre, 24‑week, placebo‑controlled, double‑blind study in patients suffering from migraine with or without aura (4‑14&nbsp;migraine days per month).</p><p>&nbsp;</p><p>955&nbsp;patients were randomised in a 1:1:1&nbsp;ratio to receive 140&nbsp;mg (n&nbsp;=&nbsp;319) or 70&nbsp;mg (n&nbsp;=&nbsp;317) erenumab or placebo (n&nbsp;=&nbsp;319). Patients were allowed to use acute headache treatments during the study.</p><p>&nbsp;</p><p>Demographics and baseline disease characteristics were balanced and comparable between study arms. Patients had a median age of 42&nbsp;years, 85% were female and 89% were white. The mean migraine frequency at baseline was approximately 8&nbsp;migraine days per month. Overall, 39% had failed one or more previous prophylactic pharmacotherapies due to lack of efficacy or poor tolerability. A total of 294&nbsp;patients (92%) for 140&nbsp;mg, 287 (91%) patients for 70&nbsp;mg and 284&nbsp;patients (89%) in the placebo arm completed the double‑blind phase.</p><p>&nbsp;</p><p>Patients treated with erenumab had a clinically relevant and statistically significant reduction from baseline in the frequency of migraine days from Months&nbsp;4 to 6 (Figure&nbsp;2) compared to patients receiving placebo. Differences from placebo were observed from Month&nbsp;1 onwards.</p><p>&nbsp;</p><p><strong>Figure&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change from baseline in monthly migraine days over time in Study&nbsp;2 (including primary endpoint over Months&nbsp;4, 5 and 6)</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_88"
 o:spid="_x0000_i1025" type="#_x0000_t75" style='width:421.5pt;height:254.25pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ahmedar2/AppData/Local/Temp/4/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="562" height="339" src="file:///C:/Users/ahmedar2/AppData/Local/Temp/4/msohtmlclip1/01/clip_image004.jpg" /></p><p><strong>Table&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Change from baseline in e</strong><strong>fficacy and patient‑reported outcomes at Weeks&nbsp;13‑24 in Study&nbsp;2</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Aimovig (erenumab)<br />140&nbsp;mg</strong></p><p>(n&nbsp;=&nbsp;318)</p></td><td style="vertical-align:top"><p><strong>Aimovig (erenumab)<br />70&nbsp;mg</strong></p><p>(n&nbsp;=&nbsp;312)</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p>(n&nbsp;=&nbsp;316)</p></td><td style="vertical-align:top"><p><strong>Treatment difference </strong>(95% CI)</p></td><td style="vertical-align:top"><p><strong>p‑value</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong><u>Efficacy outcomes</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>MMD</strong></p><p>Mean change<br />(95% CI)</p><p>Baseline (SD)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑3.7<br />(‑4.0, ‑3.3)</p><p>8.3 (2.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑3.2<br />(‑3.6, ‑2.9)</p><p>8.3 (2.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑1.8<br />(‑2.2, ‑1.5)</p><p>8.2 (2.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>70&nbsp;mg: ‑1.4 (‑1.9, ‑0.9)<br />140&nbsp;mg: ‑1.9 (‑2.3, ‑1.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Both</p><p>&lt;0.001<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge;50% MMD responders</strong></p><p>Percentage [%]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>50.0%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>43.3%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>26.6%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>n/a</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Both &lt;0.001<sup>a,d</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge;75% MMD </strong><strong>responders</strong></p><p>Percentage [%]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>22.0%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>20.8%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>7.9%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>n/a</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>n/a<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Monthly acute migraine-specific medication days</strong></p><p>Mean change<br />(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>‑1.6</p><p>(‑1.8, ‑1.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>‑1.1</p><p>(‑1.3, ‑0.9)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>‑0.2</p><p>(‑0.4, 0.0)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>70&nbsp;mg: ‑0.9(‑1.2, ‑0.6)</p><p>140&nbsp;mg: ‑1.4 (‑1.7, ‑1.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Both &lt;0.001<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (SD)</p></td><td style="vertical-align:top"><p>3.4 (3.5)</p></td><td style="vertical-align:top"><p>3.2 (3.4)</p></td><td style="vertical-align:top"><p>3.4 (3.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong><u>Patient‑reported outcome measures</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HIT</strong>‑<strong>6</strong></p><p>Mean change<sup>c</sup><br />(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑6.9</p><p>(‑7.6, ‑6.3)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑6.7</p><p>(‑7.4, ‑6.0)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>‑4.6<br />(‑5.3, ‑4.0)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>70&nbsp;mg: ‑2.1 (‑3.0, ‑1.1)</p><p>140&nbsp;mg: ‑2.3 (‑3.2, ‑1.3)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n/a<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>MIDAS (modified) total</strong></p><p>Mean change<sup>c</sup><br />(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>‑7.5<br />(‑8.3, ‑6.6)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>‑6.7<br />(‑7.6, ‑5.9)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>‑4.6<br />(‑5.5, ‑3.8)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>70&nbsp;mg: ‑2.1 (‑3.3, ‑0.9)</p><p>140&nbsp;mg: ‑2.8 (‑4.0, ‑1.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n/a<sup>b</sup></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>CI = confidence interval; MMD = monthly migraine days; HIT‑6 = Headache Impact Test; MIDAS = Migraine Disability Assessment; n/a = not applicable.</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the secondary endpoints, all p‑values are reported as unadjusted p‑values and are statistically significant after adjustment for multiple comparisons.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For exploratory endpoints, no p‑value was presented.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For HIT-6: Change and reduction from baseline were evaluated in the last 4&nbsp;weeks of the 12‑week double‑blind treatment phase. For MIDAS: Change and reduction from baseline were evaluated over 24&nbsp;weeks. For data collection a recall period of 1&nbsp;month has been used.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p value is calculated based on the odds ratios.</p></td></tr></tbody></table><p>&nbsp;</p><p>In patients failing one or more prophylactic pharmacotherapies the treatment difference for the reduction of MMD observed between erenumab 140&nbsp;mg and placebo was ‑2.5 (95% CI: ‑3.4, ‑1.7) and between erenumab 70&nbsp;mg and placebo ‑2.0 (95% CI: ‑2.8, ‑1.2). There was also a higher proportion of subjects treated with erenumab who achieved at least 50% reduction of MMD compared to placebo (39.7% for 140&nbsp;mg and 38.6% for 70&nbsp;mg, with an odds ratio of 3.1 [95% CI: 1.7, 5.5] and 2.9 [95% CI: 1.6, 5.3], respectively).</p><p>&nbsp;</p><p>Efficacy was sustained up to 1&nbsp;year in the active re-randomisation part of Study&nbsp;2. Patients were re‑randomised in the active treatment phase (ATP) to 70&nbsp;mg or 140&nbsp;mg erenumab. 79.8% completed the entire study out to 52&nbsp;weeks. The reduction in monthly migraine days from baseline to Week&nbsp;52 was ‑4.22 in the 70&nbsp;mg ATP group and ‑4.64&nbsp;days in the 140&nbsp;mg ATP group. At Week&nbsp;52, the proportion of subjects who achieved a &ge;50% reduction in MMD from baseline was 61.0% in the 70&nbsp;mg ATP and 64.9% in the 140&nbsp;mg ATP group.</p><p>&nbsp;</p><p><em>Long-term follow-up study</em></p><p>Following a placebo-controlled study, 383&nbsp;patients continued in an open-label treatment phase over 5&nbsp;years initially receiving erenumab 70&nbsp;mg (median exposure: 2.0&nbsp;years), of which 250&nbsp;patients increased their dose to 140&nbsp;mg (median exposure: 2.7&nbsp;years). 214 completed the open-label treatment phase of 5&nbsp;years. Of the 383&nbsp;patients, 168 (43.9%) discontinued with the most common reasons being patient request (84&nbsp;patients; 21.9%), adverse events (19&nbsp;patients; 5.0%), lost to follow-up (14&nbsp;patients; 3.7%) and lack of efficacy (12&nbsp;patients; 3.1%). The results indicate that efficacy was sustained for up to 5&nbsp;years in the open‑label treatment phase of the study.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Aimovig in prevention of migraine headaches in one or more subsets of the paediatric population (see section&nbsp;4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Erenumab exhibits non‑linear kinetics as a result of binding to the CGRP‑R receptor. However, at therapeutically relevant doses, the pharmacokinetics of erenumab following subcutaneous dosing every 4&nbsp;weeks are predominantly linear due to saturation of binding to CGRP-R. Subcutaneous administration of a 140&nbsp;mg once monthly dose and a 70&nbsp;mg once monthly dose in healthy volunteers resulted in a C<sub>max</sub> mean (standard deviation [SD]) of 15.8&nbsp;(4.8)&nbsp;&micro;g/ml and 6.1&nbsp;(2.1)&nbsp;&micro;g/ml, respectively, and AUC<sub>last</sub> mean (SD) of 505&nbsp;(139)&nbsp;day*&micro;g/ml and 159&nbsp;(58)&nbsp;day*&micro;g/ml, respectively.</p><p>&nbsp;</p><p>Less than 2‑fold accumulation was observed in trough serum concentrations following 140&nbsp;mg doses administered subcutaneously every 4&nbsp;weeks and serum trough concentrations approached steady state by 12&nbsp;weeks of dosing.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>Following a single subcutaneous dose of 140&nbsp;mg or 70&nbsp;mg erenumab administered to healthy adults, median peak serum concentrations were attained in 4 to 6&nbsp;days, and estimated absolute bioavailability was 82%.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Following a single 140&nbsp;mg intravenous dose, the mean (SD) volume of distribution during the terminal phase (Vz) was estimated to be 3.86&nbsp;(0.77)&nbsp;l.</p><p>&nbsp;</p><p><u>Biotransformation / Elimination</u></p><p>&nbsp;</p><p>Two elimination phases were observed for erenumab. At low concentrations, the elimination is predominately through saturable binding to target (CGRP‑R), while at higher concentrations the elimination of erenumab is largely through a non‑specific proteolytic pathway. Throughout the dosing period erenumab is predominantly eliminated via a non‑specific proteolytic pathway with the effective half‑life of 28&nbsp;days.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Patients with renal impairment</u></em></p><p>Patients with severe renal impairment (eGFR &lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>) have not been studied. Population pharmacokinetic analysis of integrated data from the Aimovig clinical studies did not reveal a difference in the pharmacokinetics of erenumab in patients with mild or moderate renal impairment relative to those with normal renal function (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em><u>Patients with hepatic impairment</u></em></p><p>No studies have been performed in patients with hepatic impairment. Erenumab, as a human monoclonal antibody, is not metabolised by cytochrome P450 enzymes and hepatic clearance is not a major clearance pathway for erenumab (see section&nbsp;4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated‑dose toxicity, toxicity to reproduction and development.</p><p>&nbsp;</p><p>Carcinogenicity studies have not been conducted with erenumab. Erenumab is not pharmacologically active in rodents. It has biological activity in cynomolgus monkeys, but this species is not an appropriate model for evaluation of tumorigenic risk. The mutagenic potential of erenumab has not been evaluated; however, monoclonal antibodies are not expected to alter DNA or chromosomes.</p><p>&nbsp;</p><p>In repeated‑dose toxicology studies there were no adverse effects in sexually mature monkeys dosed up to 150&nbsp;mg/kg subcutaneously twice weekly for up to 6&nbsp;months at systemic exposures up to 123‑fold and 246‑fold higher than the clinical dose of 140&nbsp;mg and 70&nbsp;mg, respectively, every 4&nbsp;weeks, based on serum AUC. There were also no adverse effects on surrogate markers of fertility (anatomical pathology or histopathology changes in reproductive organs) in these studies.</p><p>&nbsp;</p><p>In a reproduction study in cynomolgus monkeys there were no effects on pregnancy, embryo‑foetal or post‑natal development (up to 6&nbsp;months of age) when erenumab was dosed throughout pregnancy at exposure levels approximately 17‑fold and 34‑fold higher than those achieved in patients receiving erenumab 140&nbsp;mg and 70&nbsp;mg, respectively, every 4&nbsp;weeks dosing regimen based on AUC. Measurable erenumab serum concentrations were observed in the infant monkeys at birth, confirming that erenumab, like other IgG antibodies, crosses the placental barrier.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sucrose <strong>73mg</strong></p><p>Polysorbate 80 <strong>0.10mg</strong></p><p>Sodium hydroxide (for pH adjustment) <strong>QS to Target PH</strong></p><p>Glacial acetic acid <strong>4.5mg</strong></p><p>Water for injections <strong>QS to Target Volume</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pre‑filled pen</u></p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C&nbsp;‑&nbsp;8&deg;C). Do not freeze.</p><p>Keep the pre‑filled pen in the outer carton in order to protect from light.</p><p>After removal from the refrigerator, Aimovig must be used within 7 days when stored at room temperature (up to 30&deg;C), or discarded. If it is stored at a higher temperature or for a longer period it must<br />be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pre‑filled pen</u></p><p>&nbsp;</p><p>Aimovig is supplied in a pre‑filled pen (1&nbsp;ml, Type&nbsp;1 glass) with a stainless steel needle and a needle cover (rubber containing latex).</p><p>&nbsp;</p><p>Aimovig is available in packs containing 1&nbsp;pre‑filled pen and in multipacks containing 3&nbsp;(3x1)&nbsp;pre‑filled pens.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before administration, the solution should be inspected visually. The solution should not be injected if it is cloudy, distinctly yellow or contains flakes or particles.</p><p>&nbsp;</p><p><u>Pre‑filled pen</u></p><p>&nbsp;</p><p>To avoid discomfort at the site of injection, the pre‑filled pen(s) should be left to stand at room temperature (up to 25&deg;C) for at least 30&nbsp;minutes before injecting. It should also be protected from direct sunlight. The entire contents of the pre‑filled pen(s) must be injected. The pen(s) must not be warmed by using a heat source such as hot water or microwave and must not be shaken.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Europharm limited, Ireland, www.Novartis.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Approved by EMA in 12/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>